Novel Organic Proteasome Inhibitors Identified by Virtual and in Vitro Screening

Citations Over TimeTop 17% of 2009 papers

Abstract

Proteasome inhibition is a promising strategy for treating cancers. Herein, we report the discovery of novel drug-like inhibitors of mammalian proteasome 20S using a multistep structure-based virtual ligand screening strategy. Sulfone- or piperazine-containing hits essentially belong to the under-represented class of noncovalent and nonpeptidic proteasome inhibitors. Several of our compounds act in the micromolar range and are cytotoxic on human tumoral cell lines. Optimization of these molecules could lead to better anticancer therapy.

Related Papers

• → Discovery of new erbB4 inhibitors: Repositioning an orphan chemical library by inverse virtual screening(2018)20 cited
• → Structure activity relationship and optimization of N-(3-(2-aminothiazol-4-yl)aryl)benzenesulfonamides as anti-cancer compounds against sensitive and resistant cells(2017)15 cited
• → Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach(2009)20 cited
• → Identification of phosphodiesterase-1 and 5 dual inhibitors by a ligand-based virtual screening optimized for lead evolution(2005)16 cited
• → Synthesis and SAR studies of a novel class of S1P1 receptor antagonists(2007)14 cited